InnoCare Secures China Breakthrough Therapy Status for Marginal Zone Lymphoma Therapy
BEIJING, Aug. 4, 2026 InnoCare Pharma announced that the China National Medical Products Administration (NMPA) Center for Drug Evaluation...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine solid tumors targeted therapy
BEIJING, Aug. 4, 2026 InnoCare Pharma announced that the China National Medical Products Administration (NMPA) Center for Drug Evaluation...
BOSTON, Mass., May 27, 2026 Solu Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast...
NORTH CHICAGO, Ill., May 27, 2026 AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved DECNUPAZâ„¢...
